Clinical Pathways, Barriers, and Infrastructure Needs in Biomarker Testing for Extrapulmonary Neuroendocrine Carcinoma

This episode, titled ‘Clinical Pathways, Barriers, and Infrastructure Needs in Biomarker Testing for Extrapulmonary Neuroendocrine Carcinoma,’ featured panelists discussing the following critical questions:

Are you utilizing clinical pathways for biomarker testing for extrapulmonary neuroendocrine carcinomas? What are the strengths and weaknesses of these?

What logistical and technical barriers exist in integrating biomarker testing into routine clinical workflows?

What infrastructure improvements are needed to support broader adoption of biomarker-driven strategies?

Led by the moderator, the expert oncologists examined the role of clinical pathways in standardizing biomarker testing for extrapulmonary neuroendocrine carcinoma (epNEC), noting that while pathways help ensure consistent use of comprehensive next-generation sequencing (NGS) and screening for actionable targets such as delta-like ligand 3 (DLL3), microsatellite instability-high (MSI-H), and tumor mutational burden (TMB), they remain incomplete and require more frequent updates to keep pace with the rapidly evolving evidence base. Aman Chauhan, Namrata Vijayvergia, Sandy Kotiah, and William Oh highlighted key logistical and technical barriers to routine biomarker testing integration, including the urgency of initiating treatment in symptomatic patients, long turnaround times for specialized tests, limited pathology expertise for rare tumors, and insufficient tissue availability. The panelists emphasized that the arrival of effective biomarker-driven therapies will be the most powerful driver of broader testing adoption, and that standardized pathology reporting templates and closed-loop communication between oncologists and pathologists are critical infrastructure improvements needed to support timely diagnosis and treatment planning.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, ‘Access and Adherence: Navigating Insurance Coverage and Real-World Barriers to Biomarker Testing in Extrapulmonary Neuroendocrine Carcinoma,’ panelists continue their discussion on extrapulmonary neuroendocrine carcinoma and highlight where biomarker tests are performed, how clinicians ensure patient adherence to testing, and the insurance coverage challenges that can delay or impede access to critical biomarker information.